BACKGROUND: Cancer 2010. (c) 2010 American Cancer Society. : Intestinal bacteria have long been implicated in colorectal cancer pathology, and many reports point to a close linkage between Streptococcus bovis biotype I (recently renamed Streptococcus gallolyticus) infections and tumors of the human colon. This work aims to investigate the humoral immune response to this bacterium during different stages of colorectal cancer. METHODS: The presence of serum antibodies against S. bovis antigen RpL7/L12, previously assigned as a potential diagnostic antigen, was evaluated in Dutch (n = 209) and American (n = 112) populations using a newly developed enzyme-linked immunosorbent assay. RESULTS: The analyses consistently showed that an immune response against this bacterial antigen was increased in polyp patients and stage I/II colorectal cancer patients as compared with asymptomatic individuals. This was not paralleled by increased antibody production to endotoxin, an intrinsic cell wall component of the majority of intestinal bacteria, which implies that the humoral immune response against RpL7/L12 is not a general phenomenon induced by the loss of colonic barrier function. Notably, increased anti-RpL7/L12 levels were not or were only mildly detected in late stage colorectal cancer patients having lymph node or distant metastasis. CONCLUSIONS: Cancer 2010. (c) 2010 American Cancer Society. : These findings are indicative of an increased exposure to antigen RpL7/L12 during early stages of colon carcinogenesis and suggest that intestinal bacteria such as S. bovis constitute a risk factor for the progression of premalignant lesions into early stage carcinomas. Clearly, the current findings emphasize the necessity for further studies on the possible etiologic relationship between intestinal bacteria and human colorectal cancer. Cancer 2010. (c) 2010 American Cancer Society.
BACKGROUND:Cancer 2010. (c) 2010 American Cancer Society. : Intestinal bacteria have long been implicated in colorectal cancer pathology, and many reports point to a close linkage between Streptococcus bovis biotype I (recently renamed Streptococcus gallolyticus) infections and tumors of the human colon. This work aims to investigate the humoral immune response to this bacterium during different stages of colorectal cancer. METHODS: The presence of serum antibodies against S. bovis antigen RpL7/L12, previously assigned as a potential diagnostic antigen, was evaluated in Dutch (n = 209) and American (n = 112) populations using a newly developed enzyme-linked immunosorbent assay. RESULTS: The analyses consistently showed that an immune response against this bacterial antigen was increased in polyppatients and stage I/II colorectal cancerpatients as compared with asymptomatic individuals. This was not paralleled by increased antibody production to endotoxin, an intrinsic cell wall component of the majority of intestinal bacteria, which implies that the humoral immune response against RpL7/L12 is not a general phenomenon induced by the loss of colonic barrier function. Notably, increased anti-RpL7/L12 levels were not or were only mildly detected in late stage colorectal cancerpatients having lymph node or distant metastasis. CONCLUSIONS:Cancer 2010. (c) 2010 American Cancer Society. : These findings are indicative of an increased exposure to antigen RpL7/L12 during early stages of colon carcinogenesis and suggest that intestinal bacteria such as S. bovis constitute a risk factor for the progression of premalignant lesions into early stage carcinomas. Clearly, the current findings emphasize the necessity for further studies on the possible etiologic relationship between intestinal bacteria and humancolorectal cancer. Cancer 2010. (c) 2010 American Cancer Society.
Authors: Shaoguang Wu; Ki-Jong Rhee; Emilia Albesiano; Shervin Rabizadeh; Xinqun Wu; Hung-Rong Yen; David L Huso; Frederick L Brancati; Elizabeth Wick; Florencia McAllister; Franck Housseau; Drew M Pardoll; Cynthia L Sears Journal: Nat Med Date: 2009-08-23 Impact factor: 53.440
Authors: Annemarie Boleij; Renée M J Schaeps; Stan de Kleijn; Peter W Hermans; Philippe Glaser; Vijay Pancholi; Dorine W Swinkels; Harold Tjalsma Journal: Infect Immun Date: 2009-09-14 Impact factor: 3.441
Authors: Annemarie Boleij; Bas E Dutilh; Guus A M Kortman; Rian Roelofs; Coby M Laarakkers; Udo F Engelke; Harold Tjalsma Journal: Mol Cell Proteomics Date: 2012-06-19 Impact factor: 5.911
Authors: Julia Butt; William J Blot; Lauren R Teras; Kala Visvanathan; Loïc Le Marchand; Christopher A Haiman; Yu Chen; Ying Bao; Howard D Sesso; Sylvia Wassertheil-Smoller; Gloria Y Ho; Lesley F Tinker; Richard M Peek; John D Potter; Timothy L Cover; Laura H Hendrix; Li-Ching Huang; Tim Waterboer; Michael Pawlita; Meira Epplein Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-07-23 Impact factor: 4.254
Authors: Ikuko Kato; Annemarie Boleij; Guus A M Kortman; Rian Roelofs; Zora Djuric; Richard K Severson; Harold Tjalsma Journal: Nutr Cancer Date: 2013 Impact factor: 2.900
Authors: Julian R Marchesi; Bas E Dutilh; Neil Hall; Wilbert H M Peters; Rian Roelofs; Annemarie Boleij; Harold Tjalsma Journal: PLoS One Date: 2011-05-24 Impact factor: 3.240
Authors: Liv Anette Bøhle; Tahira Riaz; Wolfgang Egge-Jacobsen; Morten Skaugen; Øyvind L Busk; Vincent G H Eijsink; Geir Mathiesen Journal: BMC Genomics Date: 2011-03-01 Impact factor: 3.969